Karyopharm Therapeutics (KPTI)
Commercializer of the XPO1 inhibitor selinexor for blood cancers.
$1.78
Pre-market0.00 (0.00%)
At close$1.78(−3.78%)
Something off on this page? Send us feedback.
Next report
Nov 2, 2026
in 60 days
EPS estimate
−$1.16
Revenue estimate
$33.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$3.60−$2.77−$4.32−$3.82−$2.23−$1.24−$2.32Pending
Estimate−$3.90−$4.21−$3.80−$3.47−$2.26−$1.45−$1.37−$1.16
Surprise+7.7%+34.2%−13.7%−10.1%+1.3%+14.5%−69.3%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$30.5M$30.0M$37.9M$44.0M$34.1M$35.1M$33.4MPending
Estimate$37.8M$35.1M$39.6M$42.1M$35.1M$31.4M$32.2M$33.5M
Surprise−19.3%−14.5%−4.1%+4.7%−2.9%+11.7%+3.8%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.16 | — | — |
| Aug 2026 | −$1.37 | −$2.32 | −69.3% |
| May 2026 | −$1.45 | −$1.24 | +14.5% |
| Feb 2026 | −$2.26 | −$2.23 | +1.3% |
| Nov 2025 | −$3.47 | −$3.82 | −10.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | −$1.16 | — | — | $33.5M | — | — | — |
| Aug 13, 2026 | −$1.37 | −$2.32 | −69.3% | $32.2M | $33.4M | +3.8% | −2.0% |
| May 14, 2026 | −$1.45 | −$1.24 | +14.5% | $31.4M | $35.1M | +11.7% | −13.8% |
| Feb 12, 2026 | −$2.26 | −$2.23 | +1.3% | $35.1M | $34.1M | −2.9% | −4.0% |
| Nov 3, 2025 | −$3.47 | −$3.82 | −10.1% | $42.1M | $44.0M | +4.7% | −6.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 11, 2025 | |||||||
| May 12, 2025 | |||||||
| Feb 19, 2025 | |||||||
| Nov 5, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 8, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 2, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 15, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 8, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 3, 2021 | |||||||
| Feb 11, 2021 | |||||||
| Nov 2, 2020 | |||||||
| Aug 4, 2020 | |||||||
| May 5, 2020 | |||||||
| Feb 13, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 28, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 15, 2018 | |||||||
| Nov 2, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 4, 2017 | |||||||
| Mar 16, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 9, 2016 | |||||||
| Mar 14, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 10, 2015 | |||||||